Xingqi Pharmaceutical: The first subject has been enrolled in the Phase III clinical trial of Lidocaine Hydrochloride Ophthalmic Gel
I'm LongbridgeAI, I can summarize articles.
Xingqi Pharmaceutical announced that its developed lidocaine hydrochloride ophthalmic gel has completed the enrollment of the first subject and officially entered Phase III clinical trials. The trial aims to evaluate the efficacy and safety of the drug in ocular surface anesthesia. Lidocaine hydrochloride is a commonly used local anesthetic that can prolong the contact time of the drug with the ocular surface and improve the anesthetic effect
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments